ALB-SARDSNCT07857928
Effect of Albumin Therapy in Mechanically Ventilated Patients With Sepsis-Associated ARDS
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below.
- Notable Start date pushed from Oct 10, 2026 to Nov 20, 2026
- Minor Secondary endpoints: details revised at 2 of 3 entries
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Ventilator-Free Days at Day 28 (VFD-28)
Timeframe: Up to 28 days from Time Zero (T0)
Cumulative Incidence of Successful Liberation from Ventilation
Timeframe: Up to 28 days from Time Zero (T0)
Secondary (3)
Cumulative Fluid Balance
Change in Oxygenation Index (PaO2/FiO2 Ratio)
28-Day All-Cause Mortality
Arms and interventions
Prospective Observational Cohort
Patients enrolled prospectively receiving current usual clinical care, which includes a targeted human albumin treatment strategy (aiming to maintain serum albumin ≥ 30 g/L) combined with protocolized fluid de-resuscitation. Treatment decisions remain entirely under the discretion of the treating clinical team.
Historical Control Cohort
Patients identified retrospectively from electronic medical records who received usual clinical care (primarily crystalloid-based fluid management without a targeted albumin protocol) prior to the routine implementation of the targeted albumin strategy.
Sites
1 site in 1 country
- The Second Affiliated Hospital of Hainan Medical UniversityHaikou, Hainan, China